
1. euro surveill. 2019 may;24(19). doi: 10.2807/1560-7917.es.2019.24.19.1800390.

piloting surveillance system hiv drug resistance european union.

van de laar mj(1), bosman a(2), pharris a(3), andersson e(4)(5), assoumou l(6),
ay e(7), bannert n(8), bartmeyer b(8), brady m(9), chaix ml(10)(11), descamps
d(12)(10), dauwe k(13), fonager j(14), hauser a(8), lunar m(15), mezei m(7),
neary m(16), poljak m(15), van sighem a(17), verhofstede c(13), amato-gauci
aj(3), broberg ek(3).

author information: 
(1)mjw van de laar consultancy, zennewijnen, netherlands.
(2)transmissible, houten, netherlands.
(3)european centre disease prevention control (ecdc), stockholm, sweden.
(4)department clinical microbiology, karolinska university laboratory,
stockholm, sweden.
(5)division clinical microbiology, department laboratory medicine,
karolinska institute, stockholm, sweden.
(6)inserm, sorbonne université, institut pierre louis d'epidémiologie et de santé
publique, paris, france.
(7)national public health institute, department retroviruses, budapest,
hungary.
(8)robert koch institute, berlin, germany.
(9)health service executive (hse), health protection surveillance centre, dublin,
ireland.
(10)paris diderot university, paris, france.
(11)laboratoire de virologie, aphp, saint louis hospital, inserm umr944, paris,
france.
(12)laboratoire de virologie, bichat-claude bernard university hospital, inserm
umr_1137, paris, france.
(13)aids reference laboratory, department diagnostic sciences, ghent
university, ghent, belgium.
(14)virus microbiological special diagnostics, infectious disease
preparedness, statens serum institut, copenhagen, denmark.
(15)institute microbiology immunology, faculty medicine, university 
ljubljana, ljubljana, slovenia.
(16)university college dublin (ucd), national virus reference laboratory, dublin,
ireland.
(17)stichting hiv monitoring, amsterdam, netherlands.

backgrounda steady increase hiv drug resistance (hivdr) demonstrated 
globally individuals initiating first-line antiretroviral therapy (art). to
support effective use art prevent spread hivdr, monitoring is
essential.aimwe piloted surveillance system transmitted hivdr assess the
feasibility implementation european level.methodall 31 countries the
european union european economic area invited retrospectively submit 
data individuals newly diagnosed hiv 2015 tested for
antiviral susceptibility art, either case-based aggregate data.
we used stanford hiv database algorithm translate genetic sequences into
levels drug resistance.resultsnine countries participated, six reporting 
case-based data 1,680 individuals four reporting aggregated data 1,402 
cases. sequence data available 1,417 cases: 14.5% individuals
(n = 244) showed resistance least one antiretroviral drug. case-based
surveillance, highest levels transmitted hivdr observed for
non-nucleoside reverse-transcriptase inhibitors (nnrtis) resistance detected
in 8.6% (n = 145), followed resistance nucleoside reverse-transcriptase
inhibitors (nrti) (5.1%; n = 85) protease inhibitors (2.0%;
n = 34).conclusionwe conclude standard reporting hivdr data feasible 
in participating countries. legal barriers data sharing, consensus on
definitions standardisation interpretation algorithms clarified 
in process enhancing european-wide hiv surveillance drug resistance
information.

doi: 10.2807/1560-7917.es.2019.24.19.1800390 
pmcid: pmc6518967
pmid: 31088600  [indexed medline]

